PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Single-Dose Prophylaxis Matches 12-Dose Courses in Elective Urological Surgery, Without Proven Equivalence

★ Editor's Pickceftriaxonecefiximecephalosporinssurgical antibiotic prophylaxisurological surgerysymptomatic urinary tract infectionasymptomatic bacteriuriaantimicrobial stewardshiprandomized controlled trialendourologyperioperative Infectious Disease / Antimicrobials

Background Information

Extended antibiotic prophylaxis shows no added benefit in urological surgery.

Prolonged antibiotic use in surgical prophylaxis can contribute to resistance without additional benefits, necessitating reevaluation of protocols. The study found a 30-day symptomatic urinary tract infection rate of 7.1% for single-dose versus 5.5% for extended prophylaxis, with no significant difference (p = 0.536). This suggests that extended antibiotic prophylaxis may not provide added benefit for preventing postoperative infections in elective urological surgery, supporting stewardship efforts. Single-dose prophylaxis may suffice for elective urological surgeries, reducing unnecessary antibiotic use.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Nayyar R, Shetty RS, Kushwaha A, Mahapatra S, Panaiyadiyan S, Singh P, Jain S, Kumar M, Kumar S, Nayak B, Seth A

Citation: Nayyar R, Shetty RS, Kushwaha A, et al. Single-dose/day versus extended antibiotic prophylaxis for elective urological surgery: a prospective randomized controlled trial. EClinicalMedicine. 2026;101:104303. doi:10.1016/j.eclinm.2026.104303

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.